BioNTech SE vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
4.6
Underperform
Overall
7.1
Buy
Quality
Health
Growth
Valuation
Sentiment
BNTX
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-40% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $130.86 (+25.5%)
18 analysts
BUY
Target $252.42 (+9.9%)
24 analysts
Fundamentals
BNTX
JNJ
—
Trailing P/E
26.6×
-23.3×
Forward P/E
18.1×
-39.6%
Profit Margin
21.8%
78.7%
Gross Margin
68.0%
-5.9%
ROE
26.4%
-23.7%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
1.59
Beta
0.33
—
Price / Book
—
$26.4B
Market Cap
$552.9B
$80 – $124
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.